{"id":"NCT00810277","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs","officialTitle":"An Open Label Study to Evaluate the Safety and Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARDs.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11-30","primaryCompletion":"2010-05-26","completion":"2010-05-26","firstPosted":"2008-12-18","resultsPosted":"2016-03-31","lastUpdate":"2017-08-03"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs. Patients will receive iv infusions of tocilizumab 8mg/kg every 4 weeks for a total of 6 infusions, either as monotherapy or in combination with their current non-biologic DMARDs.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)","timeFrame":"Baseline up to Week 24","effectByArm":[{"arm":"Tocilizumab","deltaMin":92.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":3,"countries":["Finland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":14},"commonTop":["Neutropenia","Infusion related reaction","Lipids increased","Nausea","Gastroenteritis"]}}